Axsome Therapeutics (AXSM) Non-Current Assets (2015 - 2026)

Axsome Therapeutics has disclosed Non-Current Assets across 12 years of filings, most recently posting $102.4 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $102.4 million, changed 0.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $410.3 million (up 16.23% YoY), and the FY2025 annual result was $100.8 million, up 20.84% from the prior year.
• Non-Current Assets came in at $102.4 million for Q1 2026 at Axsome Therapeutics, up from $100.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $103.9 million in Q3 2025 to a low of $1.7 million in Q1 2022.
• The 5-year median for Non-Current Assets is $85.8 million (2022), against an average of $85.2 million.
• Across the five-year window, Non-Current Assets soared 6675.02% in 2022 and decreased 7.58% in 2024, its largest moves.
• Axsome Therapeutics' Non-Current Assets stood at $85.8 million in 2022, then retreated by 2.17% to $84.0 million in 2023, then slipped by 0.64% to $83.4 million in 2024, then advanced by 20.84% to $100.8 million in 2025, then gained by 1.57% to $102.4 million in 2026.
• The last three Non-Current Assets figures came in at $102.4 million (Q1 2026), $100.8 million (Q4 2025), and $103.9 million (Q3 2025), per Business Quant data.